hippuric acid has been researched along with Uremia in 57 studies
hippuric acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #4591
N-benzoylglycine : An N-acylglycine in which the acyl group is specified as benzoyl.
Uremia: A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hippuric acid has been recognized as a potential marker of uremic toxicity in chronic renal failure." | 5.27 | Correlation of a colorimetric and a HPLC method for the determination of serum hippuric acid concentrations in uremia. ( De Smet, R; Ringoir, S; Schoots, A; Vanholder, R, 1988) |
| "Total p-cresylsulfate (PCS), indoxyl sulfate (IS) and hippuric acid (HA) are harmful uremic toxins known to be elevated in patients with uremia." | 4.02 | Associations among total p-cresylsulfate, indoxyl sulfate and hippuric acid levels with hemodialysis quality indicators in maintenance hemodialysis patients. ( Chung, FM; Hsuan, CF; Hung, WC; Lee, TL; Lee, YJ; Lu, YC; Tsai, IT; Wang, CP; Wei, CT; Wu, CC; Yu, TH, 2021) |
| " Differentiated rhabdomyosarcoma cells were pre-treated with the uremic toxins for seven days, and then the cells were treated with pravastatin or simvastatin." | 3.80 | Uremic toxins enhance statin-induced cytotoxicity in differentiated human rhabdomyosarcoma cells. ( Furukubo, T; Izumi, S; Minegaki, T; Nishiguchi, K; Oda, T; Ogino, H; Shinmoto, T; Tachiki, H; Tsujimoto, M; Uchiyama, H; Yamakawa, T; Yoshida, T, 2014) |
| "Plasma concentrations of four substances, a pyridine derivative (S7a), uric acid (UA), hippuric acid (HA) and kynurenic acid (KA), suspected as uremic toxins in dogs were determined in dogs with experimentally induced uremia by the ligations of renal arteries, spontaneous uremic dog patients and normal dogs." | 3.69 | Plasma concentrations of substances suspected as uremic toxins in experimentally induced and spontaneous uremic dogs. ( Kawamura, M; Nishimura, R; Ohashi, F; Sasaki, N; Takeuchi, A, 1994) |
| " The uptake of liposomes by direct incubation in vitro showed an obvious dose-response relationship for p-cresyl sulfate (PCS) and indoxyl sulfate (IS) but not for hippuric acid (HA)." | 1.51 | Increasing the removal of protein-bound uremic toxins by liposome-supported hemodialysis. ( Ding, F; Li, Y; Liu, T; Ma, S; Shi, Y; Tian, H; Wang, W; Wang, Y; Zhu, Q, 2019) |
| " Plasma clearance decreased as dosage increased from 0." | 1.33 | Renal clearance of endogenous hippurate correlates with expression levels of renal organic anion transporters in uremic rats. ( Deguchi, T; Lindup, WE; Otagiri, M; Suenaga, A; Takemoto, M; Uehara, N, 2005) |
| "Hippuric acid removal was more pronounced than that of the remaining protein-bound compounds (P<0." | 1.31 | Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. ( De Smet, R; Dhondt, A; Duym, P; Lameire, N; Lesaffer, G; Vanholder, R, 2000) |
| " It is concluded that some of the protein binding inhibitors have toxic effects on cell function of various tissues and play a role in pathophysiology of uremia." | 1.28 | [Study on the uremic protein binding inhibitors as uremic toxin: toxic effect on erythroid colony formation, lymphocyte blast formation and renal function]. ( Kawashima, Y, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (21.05) | 18.7374 |
| 1990's | 11 (19.30) | 18.2507 |
| 2000's | 14 (24.56) | 29.6817 |
| 2010's | 16 (28.07) | 24.3611 |
| 2020's | 4 (7.02) | 2.80 |
| Authors | Studies |
|---|---|
| Motojima, M | 1 |
| Hosokawa, A | 1 |
| Yamato, H | 1 |
| Muraki, T | 1 |
| Yoshioka, T | 1 |
| Deguchi, T | 4 |
| Ohtsuki, S | 1 |
| Otagiri, M | 5 |
| Takanaga, H | 1 |
| Asaba, H | 1 |
| Mori, S | 1 |
| Terasaki, T | 2 |
| Kusuhara, H | 1 |
| Takadate, A | 2 |
| Endou, H | 1 |
| Sugiyama, Y | 1 |
| Sun, H | 1 |
| Huang, Y | 1 |
| Frassetto, L | 1 |
| Benet, LZ | 1 |
| Fabresse, N | 1 |
| Larabi, IA | 1 |
| Abe, E | 1 |
| Lamy, E | 1 |
| Rigothier, C | 2 |
| Massy, ZA | 1 |
| Alvarez, JC | 2 |
| Catros, S | 1 |
| Bénard, A | 1 |
| Samot, J | 1 |
| Quintin, O | 1 |
| Combe, C | 1 |
| Larabi, I | 1 |
| Massy, Z | 2 |
| Yen, SC | 1 |
| Liu, ZW | 1 |
| Juang, RS | 1 |
| Sahoo, S | 1 |
| Huang, CH | 1 |
| Chen, P | 1 |
| Hsiao, YS | 1 |
| Fang, JT | 1 |
| Nerusu, A | 1 |
| Vaikuntapu, PR | 1 |
| Chinthapalli, DK | 1 |
| Podile, AR | 1 |
| Subramanyam, R | 1 |
| Lu, YC | 1 |
| Wu, CC | 1 |
| Tsai, IT | 1 |
| Hung, WC | 1 |
| Lee, TL | 1 |
| Hsuan, CF | 1 |
| Yu, TH | 1 |
| Wei, CT | 1 |
| Chung, FM | 1 |
| Lee, YJ | 1 |
| Wang, CP | 1 |
| Deltombe, O | 3 |
| de Loor, H | 1 |
| Glorieux, G | 6 |
| Dhondt, A | 4 |
| Van Biesen, W | 3 |
| Meijers, B | 1 |
| Eloot, S | 5 |
| Shafi, T | 1 |
| Sirich, TL | 1 |
| Meyer, TW | 1 |
| Hostetter, TH | 1 |
| Plummer, NS | 1 |
| Hwang, S | 1 |
| Melamed, ML | 1 |
| Banerjee, T | 1 |
| Coresh, J | 1 |
| Powe, NR | 1 |
| Pavlenko, D | 1 |
| Giasafaki, D | 1 |
| Charalambopoulou, G | 1 |
| van Geffen, E | 1 |
| Gerritsen, KGF | 1 |
| Steriotis, T | 1 |
| Stamatialis, D | 1 |
| Shi, Y | 1 |
| Wang, Y | 1 |
| Ma, S | 1 |
| Liu, T | 1 |
| Tian, H | 1 |
| Zhu, Q | 1 |
| Wang, W | 1 |
| Li, Y | 1 |
| Ding, F | 1 |
| Chinnappa, S | 1 |
| Tu, YK | 1 |
| Yeh, YC | 1 |
| Vanholder, R | 8 |
| Mooney, A | 1 |
| Lin, YT | 1 |
| Wu, PH | 1 |
| Lee, HH | 1 |
| Mubanga, M | 1 |
| Chen, CS | 1 |
| Kuo, MC | 1 |
| Chiu, YW | 1 |
| Kuo, PL | 1 |
| Hwang, SJ | 1 |
| Marzouki, S | 1 |
| Masereeuw, R | 1 |
| Schneditz, D | 1 |
| Prokopienko, AJ | 1 |
| West, RE | 1 |
| Stubbs, JR | 1 |
| Nolin, TD | 1 |
| Neirynck, N | 1 |
| Barnes, KJ | 1 |
| Rowland, A | 1 |
| Polasek, TM | 1 |
| Miners, JO | 1 |
| Uchiyama, H | 1 |
| Tsujimoto, M | 1 |
| Shinmoto, T | 1 |
| Ogino, H | 1 |
| Oda, T | 1 |
| Yoshida, T | 1 |
| Furukubo, T | 1 |
| Izumi, S | 1 |
| Yamakawa, T | 1 |
| Tachiki, H | 1 |
| Minegaki, T | 1 |
| Nishiguchi, K | 1 |
| Lauri, K | 1 |
| Tanner, R | 1 |
| Jerotskaja, J | 1 |
| Luman, M | 1 |
| Fridolin, I | 1 |
| Kikuchi, K | 1 |
| Itoh, Y | 1 |
| Tateoka, R | 1 |
| Ezawa, A | 1 |
| Murakami, K | 1 |
| Niwa, T | 2 |
| Boelaert, J | 1 |
| Lynen, F | 1 |
| Van Landschoot, M | 1 |
| Waterloos, MA | 1 |
| Sandra, P | 1 |
| Fagugli, RM | 1 |
| De Smet, R | 5 |
| Buoncristiani, U | 1 |
| Lameire, N | 3 |
| Brunet, P | 1 |
| Dou, L | 1 |
| Cerini, C | 1 |
| Berland, Y | 1 |
| Takemoto, M | 1 |
| Uehara, N | 1 |
| Lindup, WE | 1 |
| Suenaga, A | 1 |
| Isozaki, K | 1 |
| Yousuke, K | 1 |
| Davilas, A | 1 |
| Koupparis, M | 1 |
| Macheras, P | 1 |
| Valsami, G | 1 |
| Sarnatskaya, VV | 1 |
| Yushko, LA | 1 |
| Sakhno, LA | 1 |
| Nikolaev, VG | 1 |
| Nikolaev, AV | 1 |
| Grinenko, DV | 1 |
| Mikhalovsky, SV | 1 |
| Dasgupta, A | 3 |
| Thompson, WC | 1 |
| Malik, S | 1 |
| Kawamura, M | 1 |
| Ohashi, F | 1 |
| Nishimura, R | 1 |
| Sasaki, N | 1 |
| Takeuchi, A | 1 |
| Dzúrik, R | 4 |
| Spustová, V | 4 |
| Lim, CF | 1 |
| Bernard, BF | 1 |
| de Jong, M | 1 |
| Docter, R | 1 |
| Krenning, EP | 1 |
| Hennemann, G | 1 |
| Sakai, T | 1 |
| Lesaffer, G | 1 |
| Duym, P | 1 |
| Krivosíková, Z | 1 |
| Gazdíková, K | 1 |
| Paul, A | 1 |
| Wells, A | 1 |
| Miyazaki, T | 1 |
| Hashimoto, N | 1 |
| Hayashi, H | 1 |
| Ise, M | 1 |
| Uehara, Y | 1 |
| Maeda, K | 1 |
| Vanholder, RC | 1 |
| De Smet, RV | 1 |
| Ringoir, SM | 1 |
| Tanaka, Y | 1 |
| Schoots, AC | 2 |
| Verheggen, TP | 1 |
| De Vries, PM | 1 |
| Everaerts, FM | 1 |
| Zimmerman, L | 1 |
| Jörnvall, H | 1 |
| Bergström, J | 1 |
| Peeters, JA | 1 |
| Gerlag, PG | 1 |
| Kawashima, Y | 2 |
| Sanaka, T | 1 |
| Sugino, N | 1 |
| Takahashi, M | 1 |
| Mizoguchi, H | 1 |
| Mabuchi, H | 2 |
| Nakahashi, H | 2 |
| Geryková, M | 2 |
| Gulyassy, PF | 3 |
| Jarrard, E | 1 |
| Stanfel, L | 1 |
| Schoots, A | 2 |
| Ringoir, S | 2 |
| Cramers, C | 1 |
| Van Landschoot, N | 1 |
| Wizemann, V | 1 |
| Botella, J | 1 |
| Bottini, AT | 1 |
| Stanfel, LA | 1 |
| Jarrard, EA | 2 |
| Depner, TA | 2 |
| Tavares-Almeida, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetic Study of Propranolol, Losartan, and Eprosartan in Healthy Volunteers and Patients With Chronic Kidney Disease[NCT01087749] | Phase 1 | 24 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Combination of Medium Cut-off Dialyzer Membrane and Diet Modification to Alleviate Residual Uremic Syndrome of Dialysis Patients[NCT04247867] | 50 participants (Anticipated) | Interventional | 2020-08-31 | Recruiting | |||
| The Effect of Combining Medium Cut Off Polyarylethersulfone-polyvinylpyrrolidone Dialysis Membrane and Diet Modification on Reducing of Inflammation Response[NCT04260412] | 50 participants (Anticipated) | Interventional | 2020-08-31 | Recruiting | |||
| A Multicentric Observational Trial on Protein Bound Uremic Toxins in Nocturnal Hemodialysis[NCT00417339] | 38 participants (Actual) | Observational | 2006-12-31 | Completed | |||
| A Multicentric Observational Study on the Removal of Protein-Bound Uremic Retention Solutes in Nocturnal Hemodialysis: A Cross-Sectional Analysis[NCT00417105] | 120 participants (Actual) | Observational | 2006-12-31 | Completed | |||
| A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury[NCT01548690] | Phase 2 | 47 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluate the effect of OCR-002 on ammonia levels in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: Baseline and 72 Hours
| Intervention | Percent Change (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 41.2 |
| Maximum Dose Level 6.65 g/24h | 16.6 |
| Maximum Dose Level 10 g/24h | 41.8 |
| Maximum Dose Level 20g/24h | 38.4 |
To evaluate the steady state pharmacokinetic and pharmacodynamic profile of OCR-002 in patients with impaired and intact renal function using urinary phenylacetylglutamine (PAGN) as a surrogate marker (NCT01548690)
Timeframe: 24 Hours after last infusion
| Intervention | micrograms per millileter (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 65.6 |
| Maximum Dose Level 6.65 g/24h | 32.2 |
| Maximum Dose Level 10 g/24h | 33.4 |
| Maximum Dose Level 20g/24h | 104.9 |
The orientation log focuses on orientation to place, time, and circumstance. There are 10 items on the orientation log, which are scored 0-3. A spontaneous correct response is awarded 3 points. A spontaneous response that is lacking or incorrect, but a correct response is provided following a logical cue is awarded 2 points. A score of 1 is given if spontaneous and cued responses are lacking or incorrect, but a correct response is provided in a recognition format. A score of 0 is given if the spontaneous, cued, or recognition format does not generate a correct answer. Scores from the 10 items are summed and the final score ranges from 0 to 30. (NCT01548690)
Timeframe: 30 Days
| Intervention | units on a scale (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 23.8 |
| Maximum Dose Level 6.65 g/24h | 24.0 |
| Maximum Dose Level 10 g/24h | 24.0 |
| Maximum Dose Level 20g/24h | 24.0 |
The West Haven Criteria (WHC) for Hepatic Encephalopathy measures the severity of encephalopathy and patient's level of consciousness. The scale ranges from 0 to 4; a minimum score of 0 represents a better outcome, and a maximum total score of 4 represents a worse outcome. A score of 0 corresponds to normal consciousness and behavior and normal neurological examination. A score of 1 corresponds to mild lack of awareness, shortened attention span, and impaired addition or subtraction; mild asterixis or tremor. A score of 2 corresponds to lethargy, disorientated or inappropriate behavior, obvious asterixis; slurred speech. A score of 3 corresponds to somnolent but arousable, gross disorientation or bizarre behavior, muscle rigidity and clonus; hyperreflexia. A score of 4 corresponds to coma and decerebrate posturing. (NCT01548690)
Timeframe: 120 hours from start of infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 2.4 |
| Maximum Dose Level 6.65 g/24h | 3.2 |
| Maximum Dose Level 10 g/24h | 1.6 |
| Maximum Dose Level 20g/24h | 1.8 |
To evaluate the safety and tolerability of OCR-002 in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 0 |
| Maximum Dose Level 6.65 g/24h | 0 |
| Maximum Dose Level 10 g/24h | 0 |
| Maximum Dose Level 20g/24h | 0 |
2 reviews available for hippuric acid and Uremia
| Article | Year |
|---|---|
Protein-bound uremic retention solutes.
Topics: Animals; Blood Proteins; Cresols; Furans; Hippurates; Homocysteine; Humans; Indican; Propionates; Re | 2003 |
Protein-bound uremic solutes: the forgotten toxins.
Topics: Animals; Cresols; Furans; Hippurates; Homocysteine; Humans; Indican; Intestinal Mucosa; Kinetics; Pr | 2001 |
2 trials available for hippuric acid and Uremia
| Article | Year |
|---|---|
Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes.
Topics: Adult; Aged; Cardiovascular Diseases; Cresols; Female; Glutamine; Hippurates; Humans; Indican; Kidne | 2017 |
Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis.
Topics: Creatinine; Cresols; Cross-Over Studies; Female; Furans; Hippurates; Humans; Indican; Indoleacetic A | 2002 |
Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis.
Topics: Creatinine; Cresols; Cross-Over Studies; Female; Furans; Hippurates; Humans; Indican; Indoleacetic A | 2002 |
Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis.
Topics: Creatinine; Cresols; Cross-Over Studies; Female; Furans; Hippurates; Humans; Indican; Indoleacetic A | 2002 |
Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis.
Topics: Creatinine; Cresols; Cross-Over Studies; Female; Furans; Hippurates; Humans; Indican; Indoleacetic A | 2002 |
53 other studies available for hippuric acid and Uremia
| Article | Year |
|---|---|
Uraemic toxins induce proximal tubular injury via organic anion transporter 1-mediated uptake.
Topics: Animals; Binding Sites; Cell Line; Cell Line, Transformed; Dose-Response Relationship, Drug; Free Ra | 2002 |
Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney.
Topics: Animals; Anions; Biological Transport; Dose-Response Relationship, Drug; Female; Furans; Indican; Ki | 2002 |
Characterization of uremic toxin transport by organic anion transporters in the kidney.
Topics: Animals; DNA, Complementary; GABA Modulators; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2004 |
Effects of uremic toxins on hepatic uptake and metabolism of erythromycin.
Topics: Animals; Cell Line; Dogs; Dose-Response Relationship, Drug; Erythromycin; Furans; Indican; Liver; Ma | 2004 |
Correlation between Saliva Levels and Serum Levels of Free Uremic Toxins in Healthy Volunteers.
Topics: Chromatography, Liquid; Healthy Volunteers; Humans; Indican; Renal Dialysis; Saliva; Sulfates; Tande | 2023 |
Association between Dental Scores and Saliva Uremic Toxins.
Topics: Chromatography, Liquid; Humans; Indican; Prospective Studies; Renal Insufficiency, Chronic; Saliva; | 2023 |
Carbon Nanotube/Conducting Polymer Hybrid Nanofibers as Novel Organic Bioelectronic Interfaces for Efficient Removal of Protein-Bound Uremic Toxins.
Topics: Adsorption; Cresols; Electronics; Hippurates; Humans; Indican; Nanotubes, Carbon; Polymers; Proteins | 2019 |
Truncated domains of human serum albumin improves the binding efficiency of uremic toxins: A surface plasmon resonance and computational approach.
Topics: Dialysis Solutions; Hippurates; Humans; Indoleacetic Acids; Melatonin; Molecular Docking Simulation; | 2020 |
Associations among total p-cresylsulfate, indoxyl sulfate and hippuric acid levels with hemodialysis quality indicators in maintenance hemodialysis patients.
Topics: Cresols; Hippurates; Humans; Indican; Quality Indicators, Health Care; Renal Dialysis; Sulfuric Acid | 2021 |
Exploring binding characteristics and the related competition of different protein-bound uremic toxins.
Topics: Binding, Competitive; Case-Control Studies; Chromatography, High Pressure Liquid; Cresols; Hippurate | 2017 |
Carbon Adsorbents With Dual Porosity for Efficient Removal of Uremic Toxins and Cytokines from Human Plasma.
Topics: Adsorption; beta 2-Microglobulin; Carbon; Cytokines; Hippurates; Humans; Indican; Porosity; Sorption | 2017 |
Increasing the removal of protein-bound uremic toxins by liposome-supported hemodialysis.
Topics: Animals; Cresols; Dialysis Solutions; Equipment Design; Hippurates; Indican; Kidney Failure, Chronic | 2019 |
Association between Protein-Bound Uremic Toxins and Asymptomatic Cardiac Dysfunction in Patients with Chronic Kidney Disease.
Topics: Adult; Arterial Pressure; Cardiac Output; Cresols; Exercise; Glucuronides; Heart Diseases; Heart Rat | 2018 |
Indole-3 acetic acid increased risk of impaired cognitive function in patients receiving hemodialysis.
Topics: Aged; Biomarkers; Blood-Brain Barrier; Brain; Capillary Permeability; Cognition; Cognitive Dysfuncti | 2019 |
Selective Transport of Protein-Bound Uremic Toxins in Erythrocytes.
Topics: Biological Transport; Cresols; Erythrocytes; Hippurates; Humans; Indican; Indoleacetic Acids; Protei | 2019 |
Development and validation of a UHPLC-MS/MS method for measurement of a gut-derived uremic toxin panel in human serum: An application in patients with kidney disease.
Topics: Blood Chemical Analysis; Chromatography, High Pressure Liquid; Cresols; Hippurates; Humans; Hydrogen | 2019 |
Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients?
Topics: Aged; Aged, 80 and over; beta 2-Microglobulin; Biomarkers; Creatinine; Cresols; Diabetes Mellitus; F | 2013 |
Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients?
Topics: Aged; Aged, 80 and over; beta 2-Microglobulin; Biomarkers; Creatinine; Cresols; Diabetes Mellitus; F | 2013 |
Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients?
Topics: Aged; Aged, 80 and over; beta 2-Microglobulin; Biomarkers; Creatinine; Cresols; Diabetes Mellitus; F | 2013 |
Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients?
Topics: Aged; Aged, 80 and over; beta 2-Microglobulin; Biomarkers; Creatinine; Cresols; Diabetes Mellitus; F | 2013 |
Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.
Topics: Benzyl Alcohol; Cresols; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Glucuro | 2014 |
Uremic toxins enhance statin-induced cytotoxicity in differentiated human rhabdomyosarcoma cells.
Topics: Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Survival; Drug Synergism; Furans; Hippurates | 2014 |
Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis.
Topics: Aged; Aged, 80 and over; Cresols; Cross-Sectional Studies; Female; Glucuronides; Hippurates; Humans; | 2015 |
HPLC study of uremic fluids related to optical dialysis adequacy monitoring.
Topics: Aged; Aged, 80 and over; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Creatinine; | 2010 |
Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry.
Topics: Adsorption; Animals; Carbon; Chromatography, Liquid; Hippurates; Indican; Kidney Failure, Chronic; M | 2010 |
A novel UPLC-MS-MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients.
Topics: Cardiovascular Diseases; Case-Control Studies; Chromatography, High Pressure Liquid; Cresols; Female | 2013 |
Renal clearance of endogenous hippurate correlates with expression levels of renal organic anion transporters in uremic rats.
Topics: Algorithms; Anesthesia; Animals; Biomarkers; Blotting, Western; Creatine; Dose-Response Relationship | 2005 |
Involvement of organic anion transporters in the efflux of uremic toxins across the blood-brain barrier.
Topics: Animals; Biological Transport; Blood-Brain Barrier; Brain; Female; Furans; Hippurates; Indoleacetic | 2006 |
In-vitro study on the competitive binding of diflunisal and uraemic toxins to serum albumin and human plasma using a potentiometric ion-probe technique.
Topics: Algorithms; Animals; Binding, Competitive; Blood Proteins; Calibration; Diflunisal; Hippurates; Huma | 2006 |
New approaches to the removal of protein-bound toxins from blood plasma of uremic patients.
Topics: Adsorption; Binding Sites; Calorimetry, Differential Scanning; Charcoal; Furans; Hemoperfusion; Hipp | 2007 |
Carbamazepine-salicylate interaction in normal and uremic sera: reduced interaction in uremic sera.
Topics: Carbamazepine; Drug Interactions; Hippurates; Humans; Salicylates; Salicylic Acid; Sulfates; Uremia | 1995 |
Fast atom bombardment mass spectrometric determination of the molecular weight range of uremic compounds that displace phenytoin from protein binding: absence of midmolecular uremic toxins.
Topics: Drug Interactions; Guanidine; Guanidines; Hippurates; Humans; In Vitro Techniques; Indican; Methylgu | 1994 |
Plasma concentrations of substances suspected as uremic toxins in experimentally induced and spontaneous uremic dogs.
Topics: Animals; Biomarkers; Blood Urea Nitrogen; Creatinine; Dog Diseases; Dogs; Female; Glomerulonephritis | 1994 |
Accumulated end products participate in glucose intolerance and insulin resistance in uremia.
Topics: Animals; Glucose; Glucose Intolerance; Hippurates; Humans; In Vitro Techniques; Insulin Resistance; | 1993 |
A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.
Topics: Adsorption; Animals; Biological Transport; Cells, Cultured; Furans; Hippurates; Humans; Indican; Iod | 1993 |
Characterization of binding site of uremic toxins on human serum albumin.
Topics: Binding Sites; Dansyl Compounds; Furans; Hippurates; Humans; Indoleacetic Acids; Indoles; Propionate | 1995 |
Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane.
Topics: Aged; Aged, 80 and over; Creatinine; Cresols; Female; Furans; Hippurates; Humans; Indican; Kidneys, | 2000 |
Hippurate participates in the correction of metabolic acidosis.
Topics: Acid-Base Equilibrium; Acidosis; Ammonia; Animals; Glutaminase; Hippurates; Humans; Kidney; Kidney F | 2001 |
Uremic sera contain inhibitors that block digitoxin-valproic acid interaction.
Topics: Anticonvulsants; Binding Sites; Binding, Competitive; Cardiotonic Agents; Digitoxin; Drug Interactio | 2001 |
Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uremic rats.
Topics: Adsorption; Animals; Carbon; Chromatography, High Pressure Liquid; Female; Hippurates; Indican; Inte | 1992 |
Assessment of urea and other uremic markers for quantification of dialysis efficacy.
Topics: Chromatography, High Pressure Liquid; Hemofiltration; Hippurates; Humans; Protein Binding; Regressio | 1992 |
[Study on the assay of uremic protein-binding inhibitors: furan compound and hippuric acid].
Topics: Blood Proteins; Chromatography, Gas; Furans; Hippurates; Humans; Middle Aged; Peritoneal Dialysis, C | 1991 |
Ultraviolet-absorbing organic anions in uremic serum separated by capillary zone electrophoresis, and quantification of hippuric acid.
Topics: Anions; Capillary Action; Chromatography, High Pressure Liquid; Electrophoresis; Hippurates; Humans; | 1990 |
Phenylacetylglutamine and hippuric acid in uremic and healthy subjects.
Topics: Blood Proteins; Creatinine; Glutamine; Hippurates; Humans; Kidney; Metabolic Clearance Rate; Protein | 1990 |
Effect of hemodialysis on serum concentrations of HPLC-analyzed accumulating solutes in uremia.
Topics: Adult; Aged; Blood Chemical Analysis; Blood Proteins; Chromatography, High Pressure Liquid; Female; | 1989 |
[Study on the uremic protein binding inhibitors as uremic toxin: toxic effect on erythroid colony formation, lymphocyte blast formation and renal function].
Topics: Animals; Cell Division; Cells, Cultured; Erythroid Precursor Cells; Hippurates; In Vitro Techniques; | 1989 |
Suppressive effect of quinolinic acid and hippuric acid on bone marrow erythroid growth and lymphocyte blast formation in uremia.
Topics: Anemia; Erythropoiesis; Hippurates; Humans; In Vitro Techniques; Lymphocyte Activation; Protein Bind | 1987 |
Profiling of endogenous ligand solutes that bind to serum proteins in sera of patients with uremia.
Topics: Blood Proteins; Chromatography, High Pressure Liquid; Hippurates; Hot Temperature; Humans; Indican; | 1986 |
Hippurate participation in the inhibition of glucose utilization in renal failure.
Topics: Animals; Blood Platelets; Blood Proteins; Brain; Erythrocytes; Glucose; Hippurates; Humans; In Vitro | 1987 |
Roles of hippurate and indoxyl sulfate in the impaired ligand binding by azotemic plasma.
Topics: Blood Proteins; Hippurates; Humans; Indican; Protein Binding; Salicylates; Salicylic Acid; Toxins, B | 1987 |
Displacement by anionic drugs of endogenous ligands bound to albumin in uremic serum.
Topics: Binding Sites; Furans; Hippurates; Humans; Indican; Indoleacetic Acids; Propionates; Protein Binding | 1988 |
Correlation of a colorimetric and a HPLC method for the determination of serum hippuric acid concentrations in uremia.
Topics: Chromatography, High Pressure Liquid; Colorimetry; Hippurates; Humans; Protein Binding; Uremia | 1988 |
Pathogenesis and consequences of the alteration of glucose metabolism in renal insufficiency.
Topics: Animals; Gluconeogenesis; Glucose; Hippurates; Humans; Insulin Resistance; Liver Glycogen; Rats; Tox | 1987 |
Hippuric acid as a marker.
Topics: Chromatography, High Pressure Liquid; Colorimetry; Hippurates; Humans; Renal Dialysis; Toxins, Biolo | 1987 |
Isolation and chemical identification of inhibitors of plasma ligand binding.
Topics: Adsorption; Chemical Phenomena; Chemistry; Hippurates; Humans; Hydrogen-Ion Concentration; Ligands; | 1986 |
Aromatic amino acid metabolites as potential protein binding inhibitors in human uremic plasma.
Topics: Amino Acids; Blood Proteins; Hippurates; Humans; Indoles; Kynurenic Acid; Protein Binding; Quinoline | 1985 |